Home › Funds › Stonepine Capital Management, LLC › NKTR

Stonepine Capital Management, LLC position in NKTR

NEKTAR THERAPEUTICS · Health Care

Stonepine Capital Management, LLC reported holding 110,000 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$6.7M, representing 5.11% of its reported portfolio and ranking #3 among its reported holdings. Stonepine Capital Management, LLC has disclosed NKTR holdings in 7 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)110.00K sh
Reported value held$6.66M
Portfolio Weight5.11%
First reportedQ1 2024
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Stonepine Capital Management, LLC's NKTR position evolved

Stonepine Capital Management, LLC first disclosed a stake in NKTR in Q1 2024 at 3,480,409 shares (US$3.3M). The position peaked in Q2 2026 at 120,654 shares, worth US$8.4M. Across 7 filings, Stonepine Capital Management, LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 110,000 shares valued at US$6.7M — a reduction of -10,654 shares quarter over quarter.. Notable position changes include a 69% increase in Q3 2025 (shares fell 26% over the following quarter), a 70% increase in Q1 2026 (shares fell 3% over the following quarter), a 42% increase in Q2 2026 (shares fell 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 3.48M $3.25M New
Q2 2025 50.20K $1.30M New
Q3 2025 85.00K $4.84M Add
Q4 2025 50.00K $2.11M Reduce
Q1 2026 85.00K $6.12M Add
Q2 2026 120.65K $8.42M Add
Q3 2026 110.00K $6.66M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NKTR and 13F data

NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 56 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NKTR

All NKTR fund holders →

FAQ

How long has Stonepine Capital Management, LLC held NKTR?

Stonepine Capital Management, LLC has disclosed NKTR holdings in 7 of the last 11 reported quarters, going back to Q1 2024.

What is Stonepine Capital Management, LLC's current position in NKTR?

As of Q3 2026, Stonepine Capital Management, LLC holds 110.00K shares of NKTR (NEKTAR THERAPEUTICS), valued at $6.66M, representing 5.11% of its reported portfolio and ranking #3.

Has Stonepine Capital Management, LLC been buying or selling NKTR?

In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC reduced its position in NKTR. The position peaked in Q2 2026 at 120.65K shares.

Which other funds hold NKTR?

Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.